Table 2.

Prostate cancer–specific survival rate by surrogate endpoints at 3- (n = 1364) and 5-year (n = 1178) landmark analyses^*

Surrogate endpoint	Total No.	Treatment failure events			Median PCSS time
		Control arm, No. (%)	Experimental arm, No. (%)	OR (95% CI)	Control arm, y	Experimental arm, y	HR (95% CI)
3-y Analysis
DM
Yes	88	61 (9)	27 (4)	2.36 (1.48 to 2.76)	5.46	5.77	0.95 (0.60 to 1.50)
No	1276	624 (91)	652 (96)		10.08	10.21	0.76 (0.51 to 1.11)
Total	1364	685 (50)	679 (50)		9.58	9.91	0.69 (0.52 to 0.93)
GCTF
Yes	412	235 (34)	177 (26)	1.48 (1.17 to 1.88)	8.46	8.80	0.81 (0.58 to 1.14)
No	952	450 (66)	502 (74)		10.29	10.31	0.88 (0.48 to 1.63)
Total	1364	685 (50)	679 (50)		9.58	9.91	0.69 (0.52 to 0.93)
5-y Analysis
DM
Yes	74	44 (8)	30 (5)	1.52 (0.94 to 2.45)	8.55	7.70	1.35 (0.65 to 2.78)
No	1104	543 (92)	561 (95)		10.39	10.53	0.70 (0.47 to 1.04)
Total	1178	587 (50)	591 (50)		8.17	10.47	0.73 (0.52 to 1.04)
GCTF
Yes	418	239 (41)	179 (30)	1.58 (1.24 to 2.01)	9.85	10.28	0.85 (0.56 to 1.30)
No	760	348 (59)	412 (70)		10.54	10.52	0.84 (0.45 to 1.57)
Total	1178	587 (50)	591 (50)		10.35	20.50	0.73 (0.52 to 1.04)

^*PCSS = prostate cancer–specific survival; Control arm = short-term androgen deprivation and radiation therapy arm; Experimental arm = long-term androgen deprivation and radiation therapy arm; OR = odds ratio of distant metastasis or general clinical treatment failure event; HR = hazard ratio of prostate cancer–specific death; CI = confidence interval; DM = distant metastasis; GCTF = general clinical treatment failure.